Senores Pharmaceuticals IPO Anchor Allocation at 10%

Senores Pharmaceuticals IPO saw a strong response from anchor investors, with 10% of the total IPO size subscribed by them. Out of the 1,48,87,723 shares on offer, anchor investors picked up 66,65,725 shares, reflecting solid confidence in the company’s prospects. The anchor allocation details were disclosed to the stock exchanges on December 19, 2024, ahead of the IPO opening on December 20, 2024.

The book-built issue of ₹582.11 crores is a combination of a fresh issue of ₹500 crores (1.28 crore shares) and an offer for sale of ₹82.11 crores (0.21 crore shares). The price band is set at ₹372 to ₹391 per share, with a face value of ₹10 per share. The minimum investment required by retail investors is ₹14,858, equivalent to one lot of 38 shares.

The Senores Pharmaceuticals IPO anchor allocation process, conducted on December 19, 2024, saw significant interest from institutional investors, with the entire allocation made at the upper end of the price band, ₹391 per share. This highlights strong demand for the company’s shares and confidence in its operational and financial strength.

The overall allocation of Senores Pharmaceuticals IPO reservation across categories is as follows:

The lock-in period for anchor investors is an essential mechanism to stabilize the stock price post-listing. For Senores Pharmaceuticals IPO, the lock-in details are as follows:

• 50% of Shares Lock-in Period: January 25, 2025.
• Remaining Shares Lock-in Period: March 26, 2025.

These lock-in requirements ensure that anchor investors retain their holdings for a specified duration, providing stability to the stock’s performance after listing.

Anchor Investors in Senores Pharmaceuticals IPO

Anchor investors play a pivotal role in boosting market confidence and aiding price discovery during an IPO. On December 19, 2024, Senores Pharmaceuticals IPO completed its anchor allocation process, raising ₹260.63 crores by allotting 66,65,725 shares to anchor investors at the upper price band of ₹391 per share. The anchor allocation witnessed participation from prominent institutional investors, showcasing their faith in the company’s potential.

Out of the total anchor allocation, 34.50% (22,99,380 shares) were allocated to domestic mutual funds through four schemes. This demonstrates strong domestic interest in the IPO and underscores the company’s market credibility.
 

Key IPO Details:

• IPO Size: ₹582.11 crores
• Shares Allocated to Anchors: 66,65,725
• Anchor Subscription Percentage: 10%
• Listing Date: December 30, 2024
• IPO Opening Date: December 20, 2024

About Senores Pharmaceuticals Limited and How to Apply for Senores Pharmaceuticals IPO

Incorporated in 2017, Senores Pharmaceuticals Limited develops and manufactures pharmaceutical products for regulated markets, including the US, Canada, and the UK, along with emerging markets. The company’s product portfolio includes a wide range of critical care injectables, tablets, and APIs catering to key therapeutic areas such as antibiotics and anti-fungal treatments.

The company operates three R&D facilities and has a US FDA-approved manufacturing facility in Ahmedabad, Gujarat. With a strong international presence in 43 countries, Senores Pharmaceuticals leverages its robust R&D capabilities to develop a differentiated portfolio of speciality and complex products.

Retail investors can bid for a minimum lot size of 38 shares within the price band of ₹372 to ₹391 per share. Applications can be made through online trading platforms or registered brokers. For more details, refer to the Red Herring Prospectus (RHP).